Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

Management of non-metastatic castration-resistant prostate cancer (nmCRPC) has undergone a paradigm shift with next-generation androgen receptor inhibitors. However, direct comparative data are not available to inform treatment decisions and/or guideline recommendations. Therefore, we performed netw...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Clin Oncol
Autori principali: Mori, Keiichiro, Mostafaei, Hadi, Pradere, Benjamin, Motlagh, Reza Sari, Quhal, Fahad, Laukhtina, Ekaterina, Schuettfort, Victor M., Abufaraj, Mohammad, Karakiewicz, Pierre I., Kimura, Takahiro, Egawa, Shin, Shariat, Shahrokh F.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Singapore 2020
Soggetti:
Review Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7572325/
https://ncbi.nlm.nih.gov/pubmed/32924096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-020-01777-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi